Bedrijfsoverzicht
CareDx, Inc. is a healthcare enterprise dedicated to enhancing clinical outcomes for transplant patients and advancing organ health through specialized diagnostic solutions in both the United States and international markets. The company operates within the Healthcare sector, specifically focusing on the Diagnostics & Research industry, where it provides critical technologies like AlloSure Kidney, a donor-derived cell-free DNA solution designed for kidney transplant monitoring, and AlloMap Heart, a gene expression-based diagnostic tool for heart health. In terms of scale, the organization employs 761 individuals and holds a market capitalization of $825.49M, generating an annual revenue of $379.80M based on trailing twelve-month data. These financial figures indicate that CareDx holds a significant position within its niche, maintaining a substantial asset base relative to its workforce size and demonstrating the ability to generate nearly half a billion dollars in revenue, which supports its ongoing research and development activities.
Financiële gezondheid
The company reported a revenue of $379.80M and an EBITDA of $-7,795,000, while the net income for the trailing twelve months stood at $-21,354,000. The substantial gap between the positive revenue and negative net income reveals a cost structure where operating expenses, likely driven by research, development, and sales efforts in the diagnostics sector, significantly erode bottom-line profitability. Despite the negative net income, CareDx maintains strong financial flexibility with free cash flow of $45.75M, indicating that the business generates sufficient cash from operations to cover its capital expenditures and working capital needs without external financing. The company's margins reflect this operational reality, with a gross margin of 67.6% suggesting efficient production of its diagnostic kits, contrasted by an operating margin of -3.5% and a profit margin of -5.6% that highlight the heavy investment costs required to sustain growth. Liquidity is robust, evidenced by a cash balance of $177.21M against total debt of $26.19M, resulting in a conservative balance sheet structure supported by a debt-to-equity ratio of 8.64 and a current ratio of 2.86. This current ratio indicates that the company possesses nearly three dollars in current assets for every dollar of current liabilities, ensuring ample short-term liquidity to meet obligations. However, the return metrics present challenges for management effectiveness, showing a return on equity of -6.3% and a return on assets of -3.2%, which suggests that, on a traditional accounting basis, the company is currently destroying shareholder value despite its strong cash position.
Waarderingsbeoordeling
Valuation metrics for CareDx present a complex picture, as the trailing P/E ratio is listed as N/A due to the negative earnings, whereas the forward P/E stands at 14.70. This disparity between the unavailable trailing multiple and the forward multiple implies that the market expects a significant turnaround in earnings trajectory or is valuing the company primarily on future growth potential rather than historical profitability. The price-to-book ratio is 2.70, indicating that the market is pricing the company at a premium of 2.7 times its net asset value, which often occurs in biotech and diagnostic firms where intellectual property and future pipeline value exceed book value. Alternative valuation metrics further illustrate this positioning, with a price-to-sales ratio of 2.17 and an EV/EBITDA of -86.08, suggesting that investors are willing to pay for revenue growth and market share rather than current earnings power. Regarding stock price metrics, CareDx traded within a 52-week range between a low of $10.96 and a high of $21.48, providing a clear context for price volatility and historical trading bounds. The beta of 2.54 is exceptionally high compared to the broader market, indicating that the stock's price volatility is more than double that of the overall market, making it a high-risk, high-volatility instrument.
Growth & Income
The company demonstrated a revenue growth rate of 25.2% year-over-year, while earnings growth is listed as N/A due to the negative earnings baseline. Since the earnings are currently negative, the revenue growth is the primary driver of expansion, implying that the company is prioritizing top-line growth and market penetration over immediate profitability. As a non-dividend payer, CareDx does not distribute a dividend yield, maintaining a payout ratio of 0.0%, which signifies that the company reinvests all available earnings and cash flows back into the business to fund research, development, and organic growth initiatives. This reinvestment strategy is consistent with the capital-intensive nature of the diagnostics industry, where funding new technologies and clinical trials is essential for long-term competitiveness. Overall, the growth and income profile of CareDx is characterized by robust revenue expansion funded by a strong cash position, but currently lacking in earnings generation and income distribution to shareholders.